Study on the Prognostic Value of Aberrant Antigen in Patients With Acute B Lymphocytic Leukemia
| Autor: | Cheng Zhang, Xian-Gui Peng, Ying-Ying Ma, Xi Zhang, Li Gao, Jun Liu, Lei Gao, Xu Tan, P Y Kong, Yao Liu |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
0301 basic medicine
Oncology Adult Male Cancer Research medicine.medical_specialty Adolescent medicine.medical_treatment T-Lymphocytes CD19 Immunophenotyping 03 medical and health sciences Young Adult 0302 clinical medicine Refractory Antigen Antigens Neoplasm Internal medicine medicine Humans Child Proportional Hazards Models biology Leukemia Prolymphocytic B-Cell business.industry Hematology Immunotherapy Middle Aged medicine.disease Prognosis Combined Modality Therapy Chimeric antigen receptor Leukemia 030104 developmental biology 030220 oncology & carcinogenesis biology.protein Female Interleukin-3 receptor business Biomarkers |
| Zdroj: | Clinical lymphoma, myelomaleukemia. 19(7) |
| ISSN: | 2152-2669 |
| Popis: | Background Approximately 30% to 60% of patients with acute B-lymphocytic leukemia (B-ALL) show as refractory or relapsed, which is one of the major causes of death in patients with B-ALL, but the methods of the treatment for relapsed/refractory B-ALL (R/R B-ALL) are limited. The chimeric antigen receptors redirected T cells (CAR-T cells) have showed a strong anti-leukemia role for B-ALL. About 90% of patients with R/R B-ALL treated with CD19-CAR-T cells achieved complete remission. However, 60% to 70% of patients relapsed after CAR-T cells treatment, which may be related to target antigen reduction or escape. New products are urgently needed to prevent and treat antigenic escapes causing recurrence. Patients and Methods In this article, we retrospectively analyzed the immunophenotype of patients with B-ALL initially diagnosed in our center from January 2010 to December 2015 to determine whether aberrant antigen expression was associated with the prognosis of patients in order to find new targets for immunotherapy. Results The results show that disease-free and overall survival in patients without aberrant antigen expression were better than patients with aberrant antigen expression. The most common abnormal antigens were CD123, CD13, and CD56. Correlation analysis showed a negative correlation between aberrant CD123 expression and both disease-free and overall survival. Conclusion Therefore, in the construction of CAR-T cells in patients with R/R B-ALL, conventional CD19 can be combined with aberrant antigens such as CD123 to form CARs with bi-specific antigens or multi-specific antigens may achieve the purpose of improving efficacy. However, more clinical trials are needed. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect